NO972311L - Anvendelse av ikke-peptidiske Bradykinin-antagonister for behandling og prevensjon av kronisk fibrogenetiske leversykdommer, akutte leversykdommer og de dermed forbundne komplikasjoner - Google Patents

Anvendelse av ikke-peptidiske Bradykinin-antagonister for behandling og prevensjon av kronisk fibrogenetiske leversykdommer, akutte leversykdommer og de dermed forbundne komplikasjoner

Info

Publication number
NO972311L
NO972311L NO972311A NO972311A NO972311L NO 972311 L NO972311 L NO 972311L NO 972311 A NO972311 A NO 972311A NO 972311 A NO972311 A NO 972311A NO 972311 L NO972311 L NO 972311L
Authority
NO
Norway
Prior art keywords
liver disease
prevention
treatment
chronic
bradykinin antagonists
Prior art date
Application number
NO972311A
Other languages
English (en)
Norwegian (no)
Other versions
NO972311D0 (no
Inventor
Holger Heitsch
Adalbert Wagner
Klaus Wirth
Max Hropot
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996120509 external-priority patent/DE19620509A1/de
Priority claimed from DE19632042A external-priority patent/DE19632042A1/de
Priority claimed from DE19639303A external-priority patent/DE19639303A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO972311D0 publication Critical patent/NO972311D0/no
Publication of NO972311L publication Critical patent/NO972311L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO972311A 1996-05-22 1997-05-21 Anvendelse av ikke-peptidiske Bradykinin-antagonister for behandling og prevensjon av kronisk fibrogenetiske leversykdommer, akutte leversykdommer og de dermed forbundne komplikasjoner NO972311L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1996120509 DE19620509A1 (de) 1996-05-22 1996-05-22 Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
DE19632042A DE19632042A1 (de) 1996-08-08 1996-08-08 Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
DE19639303A DE19639303A1 (de) 1996-09-25 1996-09-25 Verwendung nicht-peptidischer Bradykinin-Antagonisten zur Behandlung und Prävention von chronisch-fibrogenetischen Lebererkrankungen, akuten Lebererkrankungen und den damit verbundenen Komplikationen
US08/858,550 US5786365A (en) 1996-05-22 1997-05-19 Use of nonpeptide bradykinin antagonists for the treatment and prevention of chronic fibrogenetic liver disorders, acute liver disorders and the complications associated therewith

Publications (2)

Publication Number Publication Date
NO972311D0 NO972311D0 (no) 1997-05-21
NO972311L true NO972311L (no) 1997-11-24

Family

ID=27438369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972311A NO972311L (no) 1996-05-22 1997-05-21 Anvendelse av ikke-peptidiske Bradykinin-antagonister for behandling og prevensjon av kronisk fibrogenetiske leversykdommer, akutte leversykdommer og de dermed forbundne komplikasjoner

Country Status (23)

Country Link
US (1) US5786365A (fr)
EP (2) EP0808627A2 (fr)
JP (1) JP4034849B2 (fr)
CN (1) CN1176102A (fr)
AT (1) ATE189389T1 (fr)
AU (1) AU2351197A (fr)
BR (1) BR9703367A (fr)
CA (1) CA2205780A1 (fr)
CZ (1) CZ154697A3 (fr)
DE (1) DE59701078D1 (fr)
DK (1) DK0808628T3 (fr)
ES (1) ES2144291T3 (fr)
GR (1) GR3033048T3 (fr)
HR (1) HRP970278A2 (fr)
HU (1) HUP9700913A1 (fr)
ID (1) ID18447A (fr)
IL (1) IL120862A0 (fr)
NO (1) NO972311L (fr)
PL (1) PL320134A1 (fr)
PT (1) PT808628E (fr)
SI (1) SI0808628T1 (fr)
SK (1) SK63097A3 (fr)
TR (1) TR199700392A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935581A (en) * 1996-07-24 1999-08-10 Kapadia; Govind J. Inhibitory effects of synthetic and natural colorants on carcinogenesis
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DE19712960A1 (de) * 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
DE69931140T2 (de) 1998-11-10 2007-02-01 Temple University Of The Commonwealth System Of Higher Education Hemmung der angiogenese durch peptidanaloge der kininogen domäne 5mit hohem molekulargewicht
US6767889B1 (en) 1998-11-10 2004-07-27 Temple University Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
JP2002529474A (ja) * 1998-11-10 2002-09-10 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 高分子量キニノゲン及びそのペプチド類似体による血管形成の抑制
US6869931B1 (en) 1998-12-16 2005-03-22 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US6445588B1 (en) 2001-01-02 2002-09-03 Motorola, Inc. Apparatus and method for securing a printed circuit board to a base plate
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
CA2603589A1 (fr) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibiteurs de l'histone desacetylase
MX2012014948A (es) * 2010-06-29 2013-05-17 Jennifer Digrazia Sistema y metodo para proteccion de apositos y herbicidas.
US12427067B2 (en) 2010-06-29 2025-09-30 Jennifer DiGrazia Wound and bandage protection system and method
US10517765B2 (en) 2010-06-29 2019-12-31 Jennifer DiGrazia Wound and bandage protection system and method
RU2514345C1 (ru) * 2012-10-09 2014-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования степени риска геморрагических осложнений при миниинвазивных хирургических вмешательствах на печени

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212182A (en) * 1990-10-03 1993-05-18 American Home Products Corpooration Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
US5438064A (en) * 1991-12-23 1995-08-01 American Home Products Corporation Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents
AU686115B2 (en) * 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
JP3049648B2 (ja) * 1993-12-13 2000-06-05 日立金属株式会社 加圧成形方法および加圧成形機
WO1996004251A1 (fr) * 1994-08-03 1996-02-15 Fujisawa Pharmaceutical Co., Ltd. Compose heterocyclique

Also Published As

Publication number Publication date
SI0808628T1 (en) 2000-04-30
CA2205780A1 (fr) 1997-11-22
EP0808627A2 (fr) 1997-11-26
HUP9700913A1 (hu) 1999-09-28
IL120862A0 (en) 1997-09-30
AU2351197A (en) 1997-11-27
GR3033048T3 (en) 2000-08-31
CZ154697A3 (en) 1997-12-17
ATE189389T1 (de) 2000-02-15
PT808628E (pt) 2000-05-31
NO972311D0 (no) 1997-05-21
JPH1045624A (ja) 1998-02-17
JP4034849B2 (ja) 2008-01-16
PL320134A1 (en) 1997-11-24
TR199700392A2 (xx) 1997-12-21
CN1176102A (zh) 1998-03-18
DE59701078D1 (de) 2000-03-09
SK63097A3 (en) 1997-12-10
ID18447A (id) 1998-04-09
EP0808628A3 (fr) 1998-01-14
EP0808628B1 (fr) 2000-02-02
ES2144291T3 (es) 2000-06-01
BR9703367A (pt) 1998-09-15
MX9703725A (es) 1997-11-29
HU9700913D0 (en) 1997-07-28
US5786365A (en) 1998-07-28
EP0808628A2 (fr) 1997-11-26
DK0808628T3 (da) 2000-06-26
HRP970278A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
NO972311L (no) Anvendelse av ikke-peptidiske Bradykinin-antagonister for behandling og prevensjon av kronisk fibrogenetiske leversykdommer, akutte leversykdommer og de dermed forbundne komplikasjoner
EA200400825A1 (ru) Способы замедления старения, а также лечения и профилактики заболеваний, связанных со старением
CO4970694A1 (es) Amlodipino y atorvastatina utiles en el tratamiento de angina de pecho, ateroesclerosis, hipertension e hiperlipidemia
CR9842A (es) Composiciones de celecoxib
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
WO2003079979A3 (fr) Procede de traitement d'insuffisance cardiaque globale
CO5550426A2 (es) Novedoso metodo terapeutico
NO971453L (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
WO2004060489A3 (fr) Traitement de l'insuffisance cardiaque chronique
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
WO2002080847A3 (fr) Utilisation d'inhibiteurs du facteur de necrose des tumeurs pour le traitement de maladies cardio-vasculaires
RU2001125117A (ru) Способ восстановительного лечения больных хроническими обструктивными болезнями легких
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
AR007209A1 (es) Utilizacion de antagonistas de bradiquinina no peptidicos para la preparacion de medicamentos utiles para el tratamiento y la prevencion deenfermedades hepaticas cronicas y fibrogeneticas, enfermedades hepaticas agudas y las complicaciones asociadas a ella
WO2000043028A3 (fr) Therapie contre une affection cardiaque chronique
WO2019221645A3 (fr) Effet de balanitis aegyptiaca sur la régression de la fibrose hépatique et de la cirrhose
RU2002108089A (ru) Способ лечения неспецифического язвенного колита
NO974956L (no) Terapeutisk sammensetning for artritis
RU2002120397A (ru) Способ лечения и профилактики тромбоэмболии лёгочной артерии
RU2005129591A (ru) Способ лечения хронической сердечной недостаточности
RU97113115A (ru) Пелоидотерапия
RU2001108719A (ru) Способ профилактики побочных эффектов для препарата фенилина при лечении тромбозов и эмболий
UA40384A (uk) Спосіб лікування хронічного гнійного верхньощелепного синуїту
RU93032336A (ru) Набор для рефлекторного воздействия